EUVIMEDEUVIMED entdecken
Crossref

Efficacy of Ustekinumab and Vedolizumab Among Postoperative Crohn’s Disease Patients as Postoperative Prophylaxis and Rescue Therapy: Real-world Data

Furkan U Ertem iD, Claudia Ramos Rivers, Amir Ali Ghaffari, Andrew R Watson, Gong Tang, Marc Schwartz, Elyse Johnston, Arthur Barrie, Janet Harrison, Jeffrey M Dueker, Doug Hartman, David G Binion

Inflammatory Bowel Diseases · 06.02.2025 · 31 (2) · 461-466

DOI: 10.1093/ibd/izae137 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Inflammatory Bowel Diseases, online erschienen am 02.07.2024. Verfasst von Furkan U Ertem und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh, Pittsburgh, PA, USA. Hauptthemen laut MEDLINE: Crohn Disease, Ustekinumab, Antibodies, Monoclonal, Humanized, Gastrointestinal Agents. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 22 Literaturangaben. Gefördert von: Department of Defense.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Almost half of patients with Crohn’s disease (CD) require bowel surgeries in their lifetime. Due to the high risk of postoperative disease recurrence and high rate of previous antitumor necrosis factor (anti-TNF) failure, often alternative therapy options such as ustekinumab (UST) and vedolizumab (VDZ) are used. We aimed to evaluate the efficacy of UST and VDZ among postoperative CD patients as postoperative prophylaxis and rescue therapy.

Methods

Consented CD patients who underwent initial ileocecal resection and were treated with UST and VDZ were included in this study. Demographics, clinical characteristics, health care utilization, endoscopy scores, and surgery outcomes were collected. Postoperative early CD recurrence was defined as a Rutgeerts endoscopic score ≥i2 within the first 2 years. The rescue therapy group was defined as patients who received either UST or VDZ after having Rutgeerts endoscopic score ≥i2 postoperatively.

Results

During 2009 to 2019, 98 CD patients were treated with UST or VDZ postoperatively. Postoperative early recurrence rates were 5% (n = 1 out of 20) and 6% (1 out of 15) for the UST and VDZ groups, respectively. Two patients from the UST group and 1 patient from the VDZ group required bowel surgery during follow-up with median drug exposure of 51 (95% confidence interval [CI], 29-61) and 30 (95% CI, 14-63) months, respectively; 55% and 69% of patients had at least 1 point of improvement on postoperative endoscopic Rutgeerts score, respectively, for UST and VDZ. Only 3 out of 40 and 1 out of 23 patients required bowel surgery during follow-up while receiving UST and VDZ as rescue therapy.

Conclusions

Both UST and VDZ were effective as postoperative therapies either as prophylaxis or rescue therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Crohn DiseaseUstekinumabAntibodies, Monoclonal, HumanizedGastrointestinal AgentsPostoperative ComplicationsHumansFemaleMaleAdultMiddle AgedRecurrenceYoung AdultTreatment OutcomeFollow-Up StudiesRetrospective StudiesSecondary Prevention

Stichwörter der Autor:innen

Rutgeerts scoreUSTVDZ: postoperative Crohn’s recurrence

Substanzen

vedolizumabUstekinumabAntibodies, Monoclonal, HumanizedGastrointestinal Agents

Autor:innen und Institutionen

  • Division of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh, Pittsburgh, PA, USA.
  • Medical Group of Carolinas, Gastroenterology, Spartanburg Regional Health System, Spartanburg, SC, USA.
  • Division of Colorectal Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
  • University of Pittsburgh, Pittsburgh, PA, USA.

ORCID-Profile: Furkan U Ertem

Förderung

  • Department of Defense

Zitieren

APA

Ertem, F. U., Rivers, C. R., Ghaffari, A. A., Watson, A. R., Tang, G., Schwartz, M., Johnston, E., Barrie, A., Harrison, J., Dueker, J. M., Hartman, D., & Binion, D. G. (2025). Efficacy of Ustekinumab and Vedolizumab Among Postoperative Crohn’s Disease Patients as Postoperative Prophylaxis and Rescue Therapy: Real-world Data. Inflammatory Bowel Diseases, 31(2), 461-466. https://doi.org/10.1093/ibd/izae137

Vancouver

Ertem FU, Rivers CR, Ghaffari AA, Watson AR, Tang G, Schwartz M, et al. Efficacy of Ustekinumab and Vedolizumab Among Postoperative Crohn’s Disease Patients as Postoperative Prophylaxis and Rescue Therapy: Real-world Data. Inflammatory Bowel Diseases. 2025;31(2):461-466. doi:10.1093/ibd/izae137

BibTeX
@article{Ertem2025,
  author = {Ertem, Furkan U and Rivers, Claudia Ramos and Ghaffari, Amir Ali and Watson, Andrew R and Tang, Gong and Schwartz, Marc and Johnston, Elyse and Barrie, Arthur and Harrison, Janet and Dueker, Jeffrey M and Hartman, Doug and Binion, David G},
  title = {Efficacy of Ustekinumab and Vedolizumab Among Postoperative Crohn’s Disease Patients as Postoperative Prophylaxis and Rescue Therapy: Real-world Data},
  journal = {Inflammatory Bowel Diseases},
  year = {2025},
  volume = {31},
  number = {2},
  pages = {461--466},
  doi = {10.1093/ibd/izae137}
}
Kostenlos starten →